Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
10:52pm, Wednesday, 24'th Sep 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate princip
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
04:01pm, Wednesday, 24'th Sep 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swis
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
11:43am, Thursday, 11'th Sep 2025
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Q1 2026 Earnings Call September 11, 2025 8:30 AM EDT Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Nicol
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
09:06am, Thursday, 11'th Sep 2025
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.87 per share a year ago.
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results
07:00am, Thursday, 11'th Sep 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal quarter ended
KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
07:06am, Wednesday, 10'th Sep 2025
KalVista Pharmaceuticals, Inc. KALV will release earnings results for the first quarter before the opening bell on Thursday, Sept. 11.
KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript
10:12pm, Sunday, 07'th Sep 2025
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Cantor Global Healthcare Conference 2025 September 3, 2025 10:55 AM EDT Company Participants Benjamin Palleiko - CEO & Director Conference Call Participan
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
07:05am, Thursday, 04'th Sep 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 04'th Sep 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted two newl
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
07:00am, Wednesday, 27'th Aug 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthc
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
04:05pm, Monday, 11'th Aug 2025
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patien
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
07:00am, Monday, 11'th Aug 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Monday, 04'th Aug 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted six newl
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
08:00am, Friday, 25'th Jul 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Med
